Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles; Glabellar lines
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2020 Planned End Date changed from 1 Jan 2021 to 31 Jan 2021.
- 17 Feb 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2020.